Company valued at $1.3 billion as investors back AI-native drug discovery platform
San Francisco, California
Chai Discovery today announced the successful close of a $130 million Series B financing, valuing the company at $1.3 billion and officially making it one of the newest unicorns in the artificial intelligence sector. The funding underscores growing investor confidence in AI-driven approaches to drug discovery and development.
The Series B round was supported by a group of new and existing investors who recognize Chai Discovery’s ability to apply advanced machine learning to accelerate the identification and optimization of novel therapeutics. The company’s platform integrates large-scale biological data, predictive modeling, and automated experimentation to shorten discovery timelines and improve decision-making early in drug development.
“This milestone reflects both the strength of our technology and the impact it is having on real drug programs,” said [CEO Name], Co-Founder and Chief Executive Officer of Chai Discovery. “Our focus has always been on building AI systems that deliver practical, measurable results for drug discovery, and this investment allows us to expand that vision significantly.”
Chai Discovery plans to use the new capital to scale its research and engineering teams, expand its proprietary data infrastructure, and advance a growing pipeline of internal and partnered therapeutic programs across multiple disease areas. The company will also deepen collaborations with biopharma partners seeking faster, more cost-effective discovery solutions.
Founded to reimagine how medicines are discovered, Chai Discovery combines AI-native model development with domain expertise in chemistry, biology, and medicine. Its approach enables rapid hypothesis generation, compound design, and prioritization, helping partners move from target selection to clinical candidates with greater speed and confidence.
With this financing, Chai Discovery joins a small group of AI-focused life sciences companies to reach unicorn status, reflecting a broader shift toward data-driven innovation as a foundation of modern drug development.
About Chai Discovery
Chai Discovery is an artificial intelligence–first drug discovery company focused on transforming how new medicines are created. By integrating advanced machine learning with deep scientific expertise, the company helps biopharma organizations accelerate discovery, reduce risk, and unlock new therapeutic opportunities.
By